Abstracts tagged "Patient reported outcomes"

Abstract Number: 0746 • ACR Convergence 2023
The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis
Jessica Gutierrez Manjarrez¹, Sydney Thib², Richard J. Cook³ and Lihi Eder⁴, ¹Women’s College Research Institute / Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Women’s College Research Institute, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Ultrasound (US) may improve characterization of psoriatic arthritis (PsA) phenotypes and help predict disease outcomes. We aimed to assess whether US phenotypes are associated…
Abstract Number: 1212 • ACR Convergence 2023
Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, YONG EUN², COMFORT ANIM-KORANTENG² and AMANDA SAMMUT², ¹NYCHH- HARLEM, Bronx, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystemic immune-mediated disease with often nonspecific symptoms, associated with recurrent flares that can be life threatening. Prevalence…
Abstract Number: 1378 • ACR Convergence 2023
The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study
Gaetano La Rocca¹, Francesco Ferro², Elena Elefante³, Silvia Fonzetti⁴, Giovanni Fulvio⁵, Inmaculada Conception Navarro Garcia³, Chiara Romei⁶, Marta Mosca³ and Chiara Baldini⁵, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴AOUP, Pisa, Italy, ⁵University of Pisa, Pisa, Italy, ⁶Department of Diagnostic Imaging, Diagnostic Radiology 2, Pisa University Hospital, Pisa, Italy
Background/Purpose: In clinical trials investigating new drugs for the management of Interstitial Lung Disease (ILD) patient reported outcomes (PRO) are increasingly employed as outcome measures…
Abstract Number: 1861 • ACR Convergence 2023
Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Eduardo Santos¹, Bayram Farisogullari², Emma Dures³, Rinie Geenen⁴ and Pedro Machado⁵, ¹Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁴Utrecht University, Vorstenbosch, Netherlands, ⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: To identify the best evidence on the efficacy of non-pharmacological interventions in reducing fatigue in people with I-RMDs and to summarise their safety in…
Abstract Number: 2036 • ACR Convergence 2023
Switch or Stay the Same? Preferences of People with Autoimmune Disease on Rituximab for Different Types of COVID-19 Vaccine Boosters
Todd Wilson¹, Paul R. Fortin², Ines Colmegna³, Sonia Theriault⁴, Nathalie Amiable⁵, Alexandra Godbout⁵ and Glen Hazlewood¹, ¹University of Calgary, Calgary, AB, Canada, ²Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Centre ARThrite - CHU de Quebec - Universite Laval, Quebec City, QC, Canada
Background/Purpose: COVID-19 vaccines are now being offered as regular boosters every 6-12 months for people with autoimmune rheumatic diseases, particularly for people on rituximab, where…
Abstract Number: 2249 • ACR Convergence 2023
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Dafna Gladman¹, Laura Coates², Maarten de Wit³, Alexis R Ogdie⁴, Ana-Maria Orbai⁵, Barbara Ink⁶, Vanessa Taieb⁷, Jérémy Lambert⁸ and Laure Gossec⁹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Irigny, France, ⁹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The PsA Impact of Disease‑12 (PsAID‑12) questionnaire is a patient (pt)-reported outcome measure assessing the impact of PsA on 12 physical, social, and psychological…
Abstract Number: 0332 • ACR Convergence 2023
Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis
Jeong Min Yu¹, John VanBuren², Angela Child², Jessica Alvey², Lisa Mandl³, Laura Pinheiro⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Ashima Makol¹⁶, Jerry Molitor¹⁷, Duncan Moore¹⁸, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah²¹, Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug²⁴, Virginia Steen²⁵, Elizabeth Volkmann²⁶ and Jessica Gordon¹, ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine College, New York, NY, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Columbia University, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁶Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁷University of Minnesota, Minneapolis, MN, ¹⁸Northwestern Memorial Hospital, Chicago, IL, ¹⁹Northwestern University, Riverside, IL, ²⁰University of Pennsylvania, Philadelphia, PA, ²¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²²Duke University, Durham, NC, ²³Victoria Shanmugam, MD, Great Falls, VA, ²⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶University of California Los Angeles, Los Angeles, CA
Background/Purpose: Skin disease is a hallmark of systemic sclerosis (SSc). The modified Rodnan skin score (mRSS) is physician performed measurement that assesses the extent and…
Abstract Number: 0462 • ACR Convergence 2023
Breastfeeding Intention in Systemic Lupus Erythematosus Patients
Susana Villamizar Pérez¹, Nicole Josianne Paris¹, Melissa Serna Góngora¹, Ariel Brener¹, Jerson Claros¹, Maria Pia Izaguirre Germain¹, Barbara Pérez Cepas², Marina Micelli³, Gabriel Sequeira¹ and Eduardo Mario Kerzberg¹, ¹Hospital Dr. JM Ramos Mejia, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital medico policial Churruca Visca, Ciudad Autonoma de Buenos Aires, Argentina, ³RELESSAR, CABA, Argentina
Background/Purpose: Breastfeeding in systemic lupus erythematosus (SLE) has received little attention and the limited data available suggest that women with SLE have lower breastfeeding rates…
Abstract Number: 0754 • ACR Convergence 2023
Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis
Agnes Loiojen¹, Elise van Mulligen², Annette van der Helm-van Mil³ and Pascal de Jong², ¹Erasmus Medical Center, department of rheumatology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the treatment and follow-up of rheumatoid arthritis (RA) patients, it has become more desirable to detect changes in disease activity through remote monitoring.…
Abstract Number: 1213 • ACR Convergence 2023
Using Patient-Reported Disease Activity in a Population-Based Cohort to Predict Systemic Lupus Erythematous Hospitalization and Emergency Room Visits
S. Sam Lim¹, Sandra Wu², Ryan Ross³, Gaobin Bao¹, Megan Richards³, Liisa Palmer³ and Gary Bryant⁴, ¹Emory University, Atlanta, GA, ²AstraZeneca, Hockessin, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that has a large range of clinical manifestations, some of which can be severe. Reducing…
Abstract Number: 1385 • ACR Convergence 2023
Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers
Joerg Ermann¹, Stephanie Sinnappan² and Alexandra Forte³, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Several sets of treatment recommendations for axial spondyloarthritis and ankylosing spondylitis (axSpA/AS) have been published. Clinical practice guidelines are not followed consistently by health…
Abstract Number: 1907 • ACR Convergence 2023
Selection of a Candidate Instrument to Assess Flare in Osteoarthritis with Content Matching with Endorsed Domains
Fabiana Queiroga¹, Marita Cross², Lara Maxwell³, Leigh Callahan⁴, sam michel Cembalo⁵, Thomas Buttel², Cindy Copenhaver⁶, Jonathan Epstein⁷, david Hunter⁸, Lauren King⁹, Lyn March² and Francis Guillemin¹⁰, ¹Université de Lorraine, Antibes, France, ²University of Sydney, Sydney, Australia, ³OMERACT, Ottawa, ON, Canada, ⁴The University of North Carolina, Chapel Hill, NC, ⁵OMERACT, Nancy, France, ⁶OMERACT, Chapel Hill, NC, ⁷Université de Lorraine, Nancy, France, ⁸Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ⁹Clinical Associate, Division of Rheumatology, St. Michael’s Hospital, Toronto, ON, Canada, ¹⁰Université de Lorraine, EA 4360 Apemac, Nancy, France
Background/Purpose: The Outcome Measures in Rheumatology group (OMERACT) developed methodological steps to select instrument(s) to assess content appropriateness of outcomes, as well as tools to…
Abstract Number: 2099 • ACR Convergence 2023
Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan
Tetsuji Sawada¹, Susumu Nishiyama², Shigemoto Igari¹, Toshihiro Matsui³ and Shigeto Tohma⁴, ¹Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, ²Kurashiki Medical Center, Kurashiki, Japan, ³NHO Sagamihara National Hospital, Kanagawa, Japan, ⁴NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: Previous studies have highlighted the influence of pain, functional impairment, and affected joint distribution on the discordance in the global assessment of disease activity…
Abstract Number: 2253 • ACR Convergence 2023
Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast
Joseph Merola¹, Philip J. Mease², April W. Armstrong³, Vibeke Strand⁴, Thomas Lehman⁵, Jiyoon Choi⁶, Brandon Becker⁶, Yichen Zhong⁷, Matthew J. Colombo⁷, Diamant Thaçi⁸, Androniki Bili⁷ and Alice B. Gottlieb⁹, ¹Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Keck School of Medicine of University of Southern California, Los Angeles, CA, ⁴Stanford University, Portola Valley, CA, ⁵Bristol Myers Squibb, Philadelphia, PA, ⁶Bristol Myers Squibb, Lawrenceville, NJ, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: As 41% of patients with psoriasis may be undiagnosed for psoriatic arthritis, treatments must relieve both dermatologic and musculoskeletal symptoms. Deucravacitinib (DEUC), an oral,…
Abstract Number: 0337 • ACR Convergence 2023
Impact of Photosensitivity on Quality of Life in Dermatomyositis
Kirubel Gebre¹, Rachita Pandya², Julianne Kleitsch², Darosa Lim³, Rui Feng³ and victoria werth⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Lancaster, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Wynnewood, PA
Background/Purpose: Photosensitivity (PS) has been documented in dermatomyositis (DM) with symptoms including aggravation of preexisting cutaneous lesions and abnormal transient erythemal responses (Cheong WK et…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].